Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
Please provide your email address to receive an email when new articles are posted on . AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of ...
Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages ...
Credit: Getty Images. The application was supported by data from a phase 3 trial that included 330 patients 6 to 17 years of age with functional constipation. The Food and Drug Administration (FDA) ...
A poster titled Cumulative Experience with Diarrhea as an Uncommon Treatment-Emergent Adverse Event in Pediatric Trials of Linaclotide for the Treatment of Functional Constipation (presentation number ...
A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...
The US Food and Drug Administration (FDA) has expanded the indication for linaclotide (Linzess) to children as young as age 6 years with functional constipation, making it the first approved treatment ...
CAMBRIDGE, Mass. & SHANGHAI--(BUSINESS WIRE)--Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat ...
How often do you poop? Yes, this is a very TMI question, but an important one. Constipation, where you’re pooping less than three times a week, is one of the most common gastrointestinal complaints ...
The goal of this study was to assess the effects of transabdominal interferential electrical stimulation (TES) versus sham stimulation in women with functional constipation. In a pilot sham-controlled ...
Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by increasing fluid in the intestines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results